S&P 500   2,997.95 (+0.28%)
DOW   27,025.88 (+0.09%)
QQQ   193.41 (+0.19%)
AAPL   234.33 (-0.02%)
FB   189.67 (+0.06%)
MSFT   139.47 (-0.67%)
GOOGL   1,253.85 (+0.87%)
AMZN   1,790.38 (+0.73%)
CGC   20.31 (+2.94%)
NVDA   192.60 (-0.83%)
MU   45.44 (+0.62%)
BABA   176.24 (-0.50%)
GE   9.07 (+1.80%)
TSLA   262.42 (+1.03%)
AMD   31.02 (+0.68%)
T   37.78 (-0.03%)
F   9.10 (+0.33%)
ACB   3.80 (+5.27%)
PRI   123.96 (+0.07%)
NFLX   293.35 (+2.47%)
BAC   30.07 (-0.33%)
GILD   65.16 (-0.29%)
DIS   132.86 (+1.53%)
S&P 500   2,997.95 (+0.28%)
DOW   27,025.88 (+0.09%)
QQQ   193.41 (+0.19%)
AAPL   234.33 (-0.02%)
FB   189.67 (+0.06%)
MSFT   139.47 (-0.67%)
GOOGL   1,253.85 (+0.87%)
AMZN   1,790.38 (+0.73%)
CGC   20.31 (+2.94%)
NVDA   192.60 (-0.83%)
MU   45.44 (+0.62%)
BABA   176.24 (-0.50%)
GE   9.07 (+1.80%)
TSLA   262.42 (+1.03%)
AMD   31.02 (+0.68%)
T   37.78 (-0.03%)
F   9.10 (+0.33%)
ACB   3.80 (+5.27%)
PRI   123.96 (+0.07%)
NFLX   293.35 (+2.47%)
BAC   30.07 (-0.33%)
GILD   65.16 (-0.29%)
DIS   132.86 (+1.53%)
Log in

Adamis Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ADMP)

$0.59
+0.02 (+3.51 %)
(As of 10/17/2019 04:00 PM ET)
Today's Range
$0.58
Now: $0.59
$0.62
50-Day Range
$0.50
MA: $0.74
$1.01
52-Week Range
$0.48
Now: $0.59
$3.29
Volume581,552 shs
Average Volume527,117 shs
Market Capitalization$36.25 million
P/E RatioN/A
Dividend YieldN/A
Beta1.36
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ADMP
CUSIPN/A
Phone858-997-2400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$15.09 million
Book Value$0.99 per share

Profitability

Net Income$-39,010,000.00
Net Margins-205.32%

Miscellaneous

Employees152
Market Cap$36.25 million
Next Earnings Date11/8/2019 (Estimated)
OptionableOptionable

Receive ADMP News and Ratings via Email

Sign-up to receive the latest news and ratings for ADMP and its competitors with MarketBeat's FREE daily newsletter.


Adamis Pharmaceuticals (NASDAQ:ADMP) Frequently Asked Questions

What is Adamis Pharmaceuticals' stock symbol?

Adamis Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMP."

How were Adamis Pharmaceuticals' earnings last quarter?

Adamis Pharmaceuticals Corp (NASDAQ:ADMP) announced its earnings results on Thursday, August, 8th. The specialty pharmaceutical company reported ($0.16) EPS for the quarter, missing the Zacks' consensus estimate of ($0.13) by $0.03. The specialty pharmaceutical company earned $5.77 million during the quarter, compared to analysts' expectations of $5.82 million. Adamis Pharmaceuticals had a negative return on equity of 86.04% and a negative net margin of 205.32%. View Adamis Pharmaceuticals' Earnings History.

When is Adamis Pharmaceuticals' next earnings date?

Adamis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, November 8th 2019. View Earnings Estimates for Adamis Pharmaceuticals.

What price target have analysts set for ADMP?

5 brokerages have issued 12 month price objectives for Adamis Pharmaceuticals' stock. Their predictions range from $1.10 to $7.00. On average, they expect Adamis Pharmaceuticals' share price to reach $4.53 in the next year. This suggests a possible upside of 666.8% from the stock's current price. View Analyst Price Targets for Adamis Pharmaceuticals.

What is the consensus analysts' recommendation for Adamis Pharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adamis Pharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Adamis Pharmaceuticals.

Has Adamis Pharmaceuticals been receiving favorable news coverage?

Media headlines about ADMP stock have trended somewhat negative this week, InfoTrie reports. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Adamis Pharmaceuticals earned a daily sentiment score of -1.4 on InfoTrie's scale. They also assigned news articles about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Adamis Pharmaceuticals.

Who are some of Adamis Pharmaceuticals' key competitors?

What other stocks do shareholders of Adamis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adamis Pharmaceuticals investors own include Synergy Pharmaceuticals (SGYP), Progenics Pharmaceuticals (PGNX), Trevena (TRVN), Sorrento Therapeutics (SRNE), Verastem (VSTM), Exelixis (EXEL), Aurinia Pharmaceuticals (AUPH), BioDelivery Sciences International (BDSI), Momo (MOMO) and Novavax (NVAX).

Who are Adamis Pharmaceuticals' key executives?

Adamis Pharmaceuticals' management team includes the folowing people:
  • Mr. Richard C. Williams, Chairman & Consultant (Age 75)
  • Dr. Dennis J. Carlo, Pres, CEO & Director (Age 76)
  • Mr. Robert O. Hopkins, VP of Fin., CFO & Sec. (Age 59)
  • Mr. David J. Marguglio, Sr. VP, Chief Bus. Officer & Director (Age 49)
  • Mr. Robert B. Rothermel, Consultant & Director (Age 75)

Who are Adamis Pharmaceuticals' major shareholders?

Adamis Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Wedbush Securities Inc. (0.14%). Company insiders that own Adamis Pharmaceuticals stock include David J Marguglio, Dennis J Phd Carlo, Karen K Daniels, Robert B Rothermel, Robert O Hopkins and Ronald B Moss. View Institutional Ownership Trends for Adamis Pharmaceuticals.

Which institutional investors are buying Adamis Pharmaceuticals stock?

ADMP stock was purchased by a variety of institutional investors in the last quarter, including Wedbush Securities Inc.. View Insider Buying and Selling for Adamis Pharmaceuticals.

How do I buy shares of Adamis Pharmaceuticals?

Shares of ADMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Adamis Pharmaceuticals' stock price today?

One share of ADMP stock can currently be purchased for approximately $0.59.

How big of a company is Adamis Pharmaceuticals?

Adamis Pharmaceuticals has a market capitalization of $36.25 million and generates $15.09 million in revenue each year. The specialty pharmaceutical company earns $-39,010,000.00 in net income (profit) each year or ($1.00) on an earnings per share basis. Adamis Pharmaceuticals employs 152 workers across the globe.View Additional Information About Adamis Pharmaceuticals.

What is Adamis Pharmaceuticals' official website?

The official website for Adamis Pharmaceuticals is http://www.adamispharmaceuticals.com/.

How can I contact Adamis Pharmaceuticals?

Adamis Pharmaceuticals' mailing address is 11682 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. The specialty pharmaceutical company can be reached via phone at 858-997-2400 or via email at [email protected]


MarketBeat Community Rating for Adamis Pharmaceuticals (NASDAQ ADMP)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  284 (Vote Outperform)
Underperform Votes:  162 (Vote Underperform)
Total Votes:  446
MarketBeat's community ratings are surveys of what our community members think about Adamis Pharmaceuticals and other stocks. Vote "Outperform" if you believe ADMP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADMP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/17/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel